Archive for the ‘Clinical Trials / Drug Trials’ Category
Friday, October 31st, 2008
DURHAM, N.C.--(BUSINESS WIRE)--Oct 31, 2008 - Argos Therapeutics today announced the presentation of details on the Company's dendritic cell-based immunotherapy process, Arcelis(TM), as well as new research into the potential of the cytokine IL-12 as an immunopotency marker. The Company's Arcelis(TM) technology is a proprietary platform for creating personalized immunotherapies ...
Posted in Clinical Trials / Drug Trials | No Comments »
Friday, October 31st, 2008
- Subanalyses from the Phase 3 SHARP and Asia-Pacific trials to be presented at 59th Annual Meeting of the American Association for the Study of Liver Diseases -WAYNE, N.J. and EMERYVILLE, Calif., October 31, 2008 /PRNewswire-FirstCall/ -- Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. today announced that new Nexavar ...
Posted in Clinical Trials / Drug Trials | No Comments »
Friday, October 31st, 2008
BURNABY, BC, Oct. 30 /CNW/ - Welichem Biotech Inc. (the "Company") (TSX-V: WBI) is pleased to announce the positive results from its Phase IIa clinical trial of its drug candidate, WBI-1001, a new, non-steroid, topical cream treatment for atopic dermatitis (AD). In the trial, two concentrations (0.5% and 1.0%) of ...
Posted in Clinical Trials / Drug Trials | No Comments »
Friday, October 31st, 2008
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct 30, 2008 - Pervasis Therapeutics, Inc., a biotechnology company pioneering biologically active therapies and devices to treat serious illnesses, today announced that data from the company's Phase 1 and Phase 2 trials of Vascugel(R) V-HEALTH (Vascular intimal Hyperplasia: Extending Arterial and venous patency, Limiting vascular Trauma, and ...
Posted in Clinical Trials / Drug Trials | No Comments »
Friday, October 31st, 2008
WESTMINSTER, Colo.--(BUSINESS WIRE)--Oct 30, 2008 - Allos Therapeutics, Inc. (Nasdaq: ALTH), a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of cancer, today announced that four abstracts describing results from pralatrexate (PDX) studies have been accepted for presentation at the 50th Annual Meeting ...
Posted in Clinical Trials / Drug Trials | No Comments »
Friday, October 31st, 2008
Patients Treated with CIMZIA® Together with Methotrexate (MTX) Experienced a Rapid and Clinically Significant Improvement in Physical Function, Pain and FatigueATLANTA (Oct. 30, 2008) — UCB announced today the online publication of pivotal study results showing CIMZIA® (certolizumab pegol), the only PEGylated anti-TNF (Tumor Necrosis Factor) together with methotrexate (MTX) ...
Posted in Clinical Trials / Drug Trials | No Comments »
Friday, October 31st, 2008
BETHESDA, Md., Oct. 30, 2008--Treatment that combines a certain type of psychotherapy with an antidepressant medication is most likely to help children with anxiety disorders <http://www.nimh.nih.gov/health/topics/anxiety-disorders/index.shtml>, but each of the treatments alone are also effective, according to a new study funded by the National Institute's of Health's National Institute of ...
Posted in Clinical Trials / Drug Trials | No Comments »
Friday, October 31st, 2008
Company Believes Generex Oral-lyn May Play Valuable Role in Treatment ParadigmWORCESTER, MA., Oct. 30, 2008 (GlobeNewswire) -- Generex Biotechnology Corporation (NasdaqCM:GNBT) (http://www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today commented on the consensus algorithm for Type 2 diabetes treatment issued by ...
Posted in Clinical Trials / Drug Trials | No Comments »
Friday, October 31st, 2008
BETHESDA, Md., Oct. 30, 2008--Researchers studying neurofibromatosis type 1 -- a rare disease in which tumors grow within nerves -- have found that the tumors are triggered by crosstalk between cells in the nerves and cells in the blood. The researchers, who were funded by the National Institutes of Health ...
Posted in Clinical Trials / Drug Trials | No Comments »
Friday, October 31st, 2008
HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Oct 30, 2008 - Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce that data about the progress of Nymox's drug development for NX-1207, the Company's investigational drug for benign prostatic hyperplasia (BPH), were presented this morning at the 84th Annual Meeting of the Western Section of the ...
Posted in Clinical Trials / Drug Trials | No Comments »
Friday, October 31st, 2008
EAGAN, Minn.--(BUSINESS WIRE)--Oct 30, 2008 - Biothera will present the results of two separate Phase I clinical trials evaluating the safety of Imprime PGG(R), the company's developmental immunotherapy cancer drug, at the International Society for Biological Therapy of Cancer on Saturday, November 1 in San Diego, Calif.Biothera has completed two ...
Posted in Clinical Trials / Drug Trials | No Comments »
Friday, October 31st, 2008
SEATTLE, October 30, 2008 /PRNewswire/ -- Nearly one third of breast cancer patients prescribed tamoxifen currently fail treatment. According to the National Foundation for Cancer Research (NFCR), this failure rate can be reduced to less than ten percent, saving 20,000 lives each year, by having patients take a simple DNA ...
Posted in Clinical Trials / Drug Trials | No Comments »
Thursday, October 30th, 2008
WARREN, N.J.--(BUSINESS WIRE)--Oct 30, 2008 - This year's Transcatheter Cardiovascular Therapeutics annual meeting, also known as TCT2008, concluded recently with two important data presentations on studies that resulted in significant clinical differences between the CYPHER(R) Sirolimus-eluting Coronary Stent and Medtronic's Endeavor(R) Stent. In both SORT OUT III and the Western ...
Posted in Clinical Trials / Drug Trials | No Comments »
Thursday, October 30th, 2008
PHILADELPHIA--(BUSINESS WIRE)--Oct 30, 2008 - Research shows that proprietary non-brain penetrant cannabinoid subtype 1 (CB1) receptor antagonists developed by Jenrin Discovery are able to produce metabolically favorable effects in peripheral tissues, including fat and liver. The research also showed for the first time that these results are achievable when CB1 ...
Posted in Clinical Trials / Drug Trials | No Comments »
Thursday, October 30th, 2008
ALBANY, N.Y.--(BUSINESS WIRE)--Oct. 30, 2008 - AMRI (NASDAQ: AMRI) reported data resulting from preclinical studies of ALB109564(a) at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, held October 21-24 in Geneva, Switzerland. ALB109564(a) is a novel analog from an established and marketed class of tubulin inhibitors, which is designed ...
Posted in Clinical Trials / Drug Trials | No Comments »
